Connected Prehabilitation Program During Neo Adjuvant Chemotherapy (TRAINING)
Multicenter Randomized Study Comparing Neo Adjuvant Chemotherapy for Patients Managed for Ovarian Cancer With or Without a Connected Prehabilitation Program
NACT is a heavy oncologic treatment, which can impair functional capacity, nutritional and emotional status. These three impairments are often ignored and not taken into account in the pre-therapeutic evaluations but are correlated with postoperative morbidity and mortality after major surgery.
Recently, a prehabilitation before surgery, including physical, nutritional and psycho-social support, has been defined. From a literature review, the maximum oxygen uptake (VO2 max) seems to constitute a strong evaluation factor reflecting physical fitness, easily measured with a cardiopulmonary exercise test (CPET) at maximal effort.
Several studies have shown beneficial effects of trimodal prehabilitation programs on postoperative functional capacity, return to daily activities and pain relief.
Home-based program and connected devices may improve the feasibility and the compliance to this program.
The hypothesis of this study is that performing a connected supervised home-based and patient-tailored multimodal prehabilitation program from diagnosis to surgery (with or without ERAS program) during NACRT, for patients managed for ovarian cancer, will limit physical fitness alteration and will positively affect postoperative outcomes.
Our study consists in an early and multidimensional (combining nutritional, physical, emotional and medical support) prehabilitation program during NACT for patients with ovarian cancer, in order to limit physical alteration before surgical treatment, and therefore improve postoperative outcomes. It will include a home-based prehabilitation program, in order to allow care access to all eligible patients.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
The main objective will be to determine if a prehabilitation program during NACT, for patients treated for an advanced ovarian cancer will limit physical alteration before major abdomino-pelvic surgery, compared to a control group without prehabilitation program. The primary endpoint will be the comparison of the variation of VO2 max, between baseline and surgery, in the prehabilitation group vs control group: VO2 max will be measured with a cardiopulmonary exercise test (CPET) at maximal effort.
This prospective, multicentric randomized control trial will be conducted in 7 French comprehensive cancer Centers or University Hospital, in compliance with inclusion criteria. After an initial evaluation, patients will be randomized in two groups: Prehabilitation group (P group) and a Control group (C group).
For the P group, after baseline evaluation, we will be offering from diagnosis to surgery, during the NACT:
- A standardized, patient-tailored preoperative physical activity training program will be performed at home, from diagnosis to surgery. Supervision will be done with connected device (connected watches) and activity will be adapted,
- A nutritional care established in respect of the SFNEP-SFNCM guidelines. Nutritional support will be adapted by a dietician according to information transmitted daily (connected body fat weight scale),
- A psychological support with coping strategies.
For the C group: Patients with ovarian cancer will undergo NACT after baseline evaluation without prehabilitation program.
After NACT, for both groups, major abdomino-pelvic surgery will be done with or without ERAS pathway, according to the practice in each center.
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Dominique GENRE, Dr
- Phone Number: +33 4 91 22 37 78
- Email: drci.up@ipc.unicancer.fr
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient must have signed the written consent,
- Age ≥ 18 years,
- Patient with advanced ovarian cancer (AOC), FIGO Stage III - IV, undergoing surgery,
- Patient with neo adjuvant chemotherapy (min 3 cycles, max 6 cycles),
- Capability to perform a cardiopulmonary exercise test (CPET)
- Patient affiliated to the national "Social Security" regimen or beneficiary of this regimen.
Exclusion Criteria:
- Patient with cognitive impairment,
- Pregnancy,
- Neoadjuvant treatment contraindications,
- Physical adapted activity program contraindication,
- No possibility to have access to connected devices or do not have a smartphone or a computer
- Patient deprived of liberty or placed under the authority of a tutor,
- Patient considered socially or psychologically unable to comply with the procedure and the required medical follow-up.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
NO_INTERVENTION: Control group
Group without prehabilitation program before surgery
|
|
|
EXPERIMENTAL: Prehabilitation group
Group will follows a prehabilitation program before surgery
|
physical, nutritional and psycho-social supports before surgery
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To determine if a prehabilitation program during NACT, for patient managed with advanced ovarian cancer (AOC) will limit physical alteration before surgery, compared to a control group without prehabilitation program (change between 3 timepoints).
Time Frame: baseline, 15 days before surgery and 3 moths before surgery
|
CHANGE of VO2 max between baseline (inclusion) and surgery (preoperative), in the prehabilitation group vs control group.
VO2 max will be measured during a cardiopulmonary exercise test (CPET).
|
baseline, 15 days before surgery and 3 moths before surgery
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
to compare physical outcomes between both groups
Time Frame: baseline, before surgery, and 3 months after surgery
|
o International Physical Activity Questionnaire (IPAQ) , administered at inclusion and at the time of surgery and after surgery
|
baseline, before surgery, and 3 months after surgery
|
|
to compare physical outcomes between both groups
Time Frame: baseline, before surgery, and 3 months after surgery
|
Muscular strength evaluated with dynamometer (brachial biceps)
|
baseline, before surgery, and 3 months after surgery
|
|
to compare Quality of Life, emotional outcomes between both groups
Time Frame: baseline, before surgery, and 3 months after surgery
|
Psychological status evaluated by the Hospital Anxiety and Depression Scale (HADS) (Annex 2)
|
baseline, before surgery, and 3 months after surgery
|
|
to compare Quality of Life, emotional outcomes between both groups
Time Frame: baseline, before surgery, and 3 months after surgery
|
Cancer related quality of life (QoL) evaluated by using the self-reported European Organization for Research and Treatment of Cancer (EORTC) core questionnaire (QLQ-C30) (Annex 3)
|
baseline, before surgery, and 3 months after surgery
|
|
to compare Quality of Life, emotional outcomes between both groups
Time Frame: baseline, before surgery, and 3 months after surgery
|
Motivation evaluated by a free interview and a coping strategy.
|
baseline, before surgery, and 3 months after surgery
|
|
to compare nutritional outcomes between both groups
Time Frame: baseline, before surgery, and 3 months after surgery
|
Change Body Mass Index (BMI)
|
baseline, before surgery, and 3 months after surgery
|
|
to compare nutritional outcomes between both groups
Time Frame: baseline, before surgery, and 3 months after surgery
|
Muscle mass evaluated with the Computed tomography-derived
|
baseline, before surgery, and 3 months after surgery
|
|
to compare nutritional outcomes between both groups
Time Frame: baseline, before surgery, and 3 months after surgery
|
skeletal muscle index measured by skeletal muscle mass cross-sectional area at L3/height2
|
baseline, before surgery, and 3 months after surgery
|
|
to compare nutritional outcomes between both groups
Time Frame: baseline, before surgery, and 3 months after surgery
|
Weight in kg
|
baseline, before surgery, and 3 months after surgery
|
|
to compare Surgical Morbidity rate between both groups
Time Frame: at day 30 and day 90 (3 months) after surgery
|
Clavien-Dindo classification
|
at day 30 and day 90 (3 months) after surgery
|
|
to compare Surgical Morbidity rate between both groups
Time Frame: at day 30 and day 90 (3 months) after surgery
|
NCI-CTCAE v 5.0 classification
|
at day 30 and day 90 (3 months) after surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Ovarian Neoplasms
- Carcinoma, Ovarian Epithelial
Other Study ID Numbers
Other Study ID Numbers
- TRAINING-01-IPC 2018-039
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.